Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioCryst Pharmaceuticals, Inc. Announces Pricing of Public Offering.


BIRMINGHAM, Ala.--(BW HealthWire)--Nov. 3, 1999--

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that its follow-on public offering of 2,000,000 shares of common stock was priced at $25.25 per share, for gross proceeds of $50.5 million.

An underwriting group composed of Salomon Smith Barney Inc., Hambrecht & Quist LLC (Logical Link Control) See "LANs" under data link protocol.

LLC - Logical Link Control
 and Raymond James & Associates, Inc. conducted the offering. The underwriters have the option to purchase up to an additional 300,000 shares of common stock to cover over-allotments, if any.

The Company plans to use the net proceeds Net Proceeds

The amount received after all costs are deducted from the sale of a piece of property or security.

Notes:
In the case of an investor selling a security, net proceeds represent the proceeds from the sale minus any trading costs (i.e. commissions).
 from this offering for research and development activities, preclinical studies preclinical studies,
n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research.
 and clinical trials, working capital and general corporate purposes.

BioCryst is a biotechnology company whose lead product candidate is a neuraminidase inhibitor neuraminidase inhibitor Infectious disease Any antiviral that inhibits neuraminidase, an enzyme essential for replication of influenza and other viruses. See Influenza.  designed to treat and prevent viral influenza.

NOTE: This news release shall not constitute an offer to sell or the solicitation or an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any such state. Copies of the prospectus relating to the offering can be obtained from Salomon Smith Barney Inc., 140 58th Street, Brooklyn, New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
 11220, Fax: 718-765-6734.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Nov 3, 1999
Words:209
Previous Article:REPEAT/eConnect Announces New E-commerce Business Model With Successful Installation of its Linux-based Internet Transaction Server.
Next Article:Shea Homes Selects bamboo.com; Shea's Model Homes are Open 24 Hours a Day With bamboo Virtual Tours.
Topics:



Related Articles
BIOCRYST REPORTS 1994 FINANCIAL RESULTS.
BIOCRYST COMPLETES $8.0 MILLION FINANCING.
BIOCRYST REPORTS FIRST QUARTER FINANCIAL RESULTS.
BioCryst Appoints W. Randall Pittman Chief Financial Officer.
BioCryst Reports 1999 Fourth Quarter and Year-end Financial Results.
BioCryst to Receive $4 Million Milestone Payment in Connection With Initiation of Phase III Studies of Oral Neuraminidase Inhibitor RWJ-270201...
Corporate Profile for BioCryst Pharmaceuticals, Inc., dated Oct. 13, 2000.
Chart on drugs in development. (HIV Pipeline).
BIOCRYST/GREEN CROSS TO DEVELOP PERAMIVIR IN SOUTH KOREA.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles